We observed a large degree of variation in CD4/CD8 compositions among individuals: CD8+ subsets ranged 32.6–87.5% in patients prior to alemtuzumab treatment, and there was a generally elevated CD8+ subset in T-LGLL patients (Fig. 1c, d). Here, CD8A is linked to T-cell large granular lymphocyte leukemia.